Lucid Diagnostics (LUCD): Debts to Book Capitalization

Lucid Diagnostics Inc. (LUCD) is expanding its presence in the early detection segment of esophageal oncology by offering unique testing systems. The business relies on the innovative EsoGuard method, which enables the detection of precancerous changes in minutes without endoscopy. The market capitalization trend on GURU.Markets is 2.45. Equipment patents and strict clinical validation requirements for insurance coverage ensure a monopoly status within the niche.

LUCD Lucid Diagnostics, Inc Debt to Book Value Ratio (07/04/2022 - 10/27/2026)

Summary analytical data breakdowns for Lucid Diagnostics, Inc. (LUCD)

- price and consensus price forecast:

Stock Price Lucid Diagnostics Inc.|LUCD - Broker Consensus Forecast

- market capitalization data:

Market Capitalization Lucid Diagnostics, Inc|LUCD - Enterprise Value

- book capitalization data:

Net Assets per Single Share Lucid Diagnostics|LUCD - Accounting Capitalization|Market Capitalization to Book Value Ratio luciddx.com|LUCD - Company Total Assets

- debt and liquidity data:

Debt to Equity Lucid Diagnostics Inc.|LUCD - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Lucid Diagnostics Inc|LUCD - Company Cumulative Debt|Debt to Book Capitalization Ratio Lucid Diagnostics, Inc

Summary company analytics:Lucid Diagnostics Inc.

Original product of Lucid Diagnostics, Inc

This indicator assesses the debt load by comparing total liabilities to the book value of equity to determine financial stability and default risks. By analyzing the financial leverage trend chart for Lucid Diagnostics Inc. (LUCD) on GURU.Markets, an investor can see the capital structure's sensitivity to external shocks, which is critical for Lucid Diagnostics Inc. (LUCD) in the event of a potential revenue decline due to the slow adoption of new diagnostic tests.

Competitors of Lucid Diagnostics Inc.